Latest MYDICAR® Stories

2010-03-23 07:00:00

LA JOLLA, Calif., March 23 /PRNewswire/ -- Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the company's lead drug candidate MYDICAR®, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon. When issued, the patent will cover the use of...

Word of the Day
  • Boughs or branches.
  • Warbling of birds in trees.